Bio-Europe 2025, Vienna
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, was pleased to attend BIO-Europe – Europe’s largest life sciences partnering event – in Vienna this November 2025.
This year with over 5,800 attendees from the life sciences industry, Physiomics’ Head of Business Development, Hayley Close and Head of Biometrics, Jesse Thissen, attended partnering meetings and networking sessions throughout the three days to explore partnerships with decision-makers of leading biotech and pharma from across the globe.
BIO-Europe allowed the Physiomics team to meet new and existing clients in person and share how our integrated services in MIDD, Biostatistics, and Bioinformatics can support smarter, faster decision-making across the development pipeline.
For more information about Physiomics’ services and partnerships visit www.physiomics.co.uk.
Enquiries:
Physiomics plc
Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 140 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.